Given recent studies demonstrating the critical intermediary function of the lipid raft-LRP8 system in the stimulation of ECs by APS, inhibitors targeting this system may alleviate clinical symptoms and serve as potential therapeutic targets for APS. Here, LRP8 is linked to autoimmune polyendocrinopathy.